https://wmpllc.org/ojs/index.php/jom/gateway/plugin/AnnouncementFeedGatewayPlugin/atom 2024-07-17T13:59:06-04:00 Open Journal Systems <p><em><strong>"What are the latest clinical applications of opioids in medicine?"</strong></em></p> <p><em><strong>"How should healthcare providers prescribe and manage patients on opioid therapies to enhance outcomes and reduce risk to the patient."</strong></em></p> <p><em><strong>"What is the latest basic science in opioids and pain pathways?"</strong></em></p> <p><em><strong>"How should I modify my practice to stay out of the legal and regulatory 'cross-hairs' in this challenging environment?"</strong></em></p> <p><strong><em>Journal of Opioid Management</em> </strong>addresses these important questions and <span style="text-decoration: underline;">many</span> more faced by medical professionals as they deal with the complexities of opioid therapies.</p> <p><em><strong>Journal of Opioid Management </strong></em>is a peer-reviewed, professional journal that addresses all aspects of the safe use and management of opioids. The Journal provides guidance to physicians and healthcare professionals on how to safely prescribe and responsibly manage these important drugs.</p> <p><em><strong>Journal of Opioid Management</strong></em> topics and features include:</p> <ul> <li>The latest basic science and clinical application of opioid therapy</li> <li>Tapering Patients Off Opioids</li> <li>Alternatives to Opioid Therapy for Pain</li> <li>Treatment of Co-Morbid Conditions, e.g. Addiction and Bipolar Disorder and Addiction</li> <li>Patient Selection for Use of Opioids to Treat Pain; Detecting Abuse, Diversion and Addiction</li> <li>Use of Opioids in Chronic Non-Cancer Patients as well as Cancer Survivors</li> <li>Opioid Education for Prescribers - Does it work?</li> <li>Updates on FDA Approvals: Abuse Deterrent Opioid Formulations and Their Applications</li> <li>Opioid Management in the midst of an opioid crisis for palliative care patients</li> <li>Rethinking Medication Treatment for Opioid Use Disorder</li> <li>Guidelines on proper opioid prescribing and compliance</li> <li>Legal issues and the ongoing regulatory environment </li> <li>Medical Marijuana and Opioids</li> <li>And Much More!</li> </ul> <p><br />Designed to meet the challenge faced by medical professionals as they prescribe opioids, <em><strong>Journal of Opioid Management</strong></em> fills what's been called "a dangerous gap" in medical literature at a time when the Federal spotlight has been switched on to the rising problem of abuse and addiction tied to these prescription painkillers.</p> <p>With an editorial review board of the world's leading experts in the field, under the leadership of Editor-in-Chief, Paul A. Sloan, MD, <em><strong>Journal of Opioid Management</strong></em> addresses all aspects of the use and safe management of opioids. It provides guidance to physicians and healthcare professionals on how to safely prescribe and responsibly manage these drugs. <strong>Subscribe today!</strong></p> https://wmpllc.org/ojs/index.php/jom/announcement/view/39 2024-07-17T13:59:06-04:00 Journal of Opioid Management

<p><img src="https://files.constantcontact.com/1c3f7b56001/823115d7-9c63-47e4-b0ed-846f7dcc603f.png?rdr=true" alt="823115d7-9c63-47e4-b0ed-846f7dcc603f.png?rdr=true" /></p> <p><strong>Call for Presentations - </strong><strong>Additional Presentations Requested</strong></p> <p><strong>Dear Reader,</strong></p> <p>On behalf of our <strong>BUPE2024-Buprenorphine in Medicine</strong> conference co-chairs, Dr. Mellar Davis and Dr. Mary Lynn McPherson, we are reaching out to recruit additional presentations for the following specific topics to round out our BUPE2024 educational site. If you have expertise in these areas, we would appreciate an abstract for a 30-60 minute recorded or live presentation. We also have a section for video posters for late-breaking research on all buprenorphine topics.</p> <p><strong>BUPE2024 Questions</strong></p> <p>Main Questions:</p> <ul> <li>Why is buprenorphine not covered by health insurance? Why is it difficult to get insurance coverage?</li> <li>Why is buprenorphine excluded from health insurance formularies of prescription drugs for pain management?</li> <li>What is the DEA’s perspective on buprenorphine being excluded from formularies?</li> <li>What is the addiction medicine community’s perspective on prescribing buprenorphine for addiction treatment?</li> <li>What challenges do pharmacists face filling buprenorphine prescriptions?</li> <li>What are the implications of converting patients from buprenorphine treatment to other opioids?</li> <li>What is the safest way to wean patients off buprenorphine treatment?</li> <li>Should there be a front-line drug for pain management instead of initially prescribing potentially addictive meds like oxycodone? Buprenorphine?!</li> <li>How does buprenorphine compare to other opioids for pain management and addiction treatment?</li> <li>How does buprenorphine compare to other opioids regarding tolerance to achieve the same analgesic effect?</li> <li>What are the clinical usages/aspects of buprenorphine? Clinical pain management vs. addiction.</li> <li>Are there advantages or disadvantages of combining buprenorphine with other opioids?</li> <li>What is the best way to convert to buprenorphine? 1-Transition to TD buprenorphine, 2- Microdose?</li> <li>Myths regarding buprenorphine.</li> <li>Why is buprenorphine used on the street?</li> <li>Rotations from buprenorphine to other opioids.</li> <li>Buprenorphine versus naloxone in reversing opioid-induced respiratory depression, is it time for consideration?</li> <li>Utilization of buprenorphine in hospice and palliative medicine.</li> <li>The use of AI for decision support when prescribing buprenorphine and other opioids</li> </ul> <p>Other ideas/topics:</p> <ul> <li>Issues on the fringe</li> <li>Practical aspects</li> <li>Conversion ratios</li> <li>Educating other physicians, families/patients</li> <li>Buprenorphine vs. another opioid</li> <li>Infographics</li> <li>Myths of buprenorphine</li> <li>A session of submitted questions that get asked on a regular basis.</li> </ul> <p>Presentation subjects we’d like to pursue:</p> <ul> <li>Health insurance</li> <li>Clinical</li> <li>Pharmacist</li> <li>Basic pharmacology</li> <li>Psychiatry</li> <li>DEA</li> <li>Basic science</li> <li>Opioid ethics</li> <li>Sons of buprenorphine</li> </ul> <p><strong>Please submit your presentation abstract by Monday, July 31, 2024, to help expand knowledge on buprenorphine's diverse role in pain management and addiction treatment. Thank You!</strong></p> <p><strong>Submission Instructions</strong></p> <p>1. <a href="https://wmpllc.org/ojs/index.php/jom/libraryFiles/downloadPublic/10">Download and complete the BUPE2024 Abstract Form</a></p> <p>2. <a href="https://wmpllc.org/ojs/index.php/jom/libraryFiles/downloadPublic/9">Download and complete the disclosure form</a> (for each individual on abstract form)</p> <p>3. <a href="https://wmpllc.org/ojs/index.php/jom/libraryFiles/downloadPublic/22">Download and complete the general release form</a> (for each presenter)</p> <p>4. Email all completed forms together to <a href="mailto:jom@pnpco.com">jom@pnpco.com</a></p> <p>For help, call 781-899 2702 ext. 108 from 9:00 AM - 5:00 PM ET.</p> <p>of email us at<a href="mailto:jom@pnpco.com"> jom@pnpco.com</a></p> <p>Deadline to Submit Forms: July 31, 2024</p>

2024-07-17T13:59:06-04:00 https://wmpllc.org/ojs/index.php/jom/announcement/view/38 2024-07-17T13:30:06-04:00 Journal of Opioid Management

<p><img src="https://files.constantcontact.com/1c3f7b56001/823115d7-9c63-47e4-b0ed-846f7dcc603f.png?rdr=true" /></p> <center><strong>Call for Presentations - </strong><strong>Additional Presentations Requested</strong></center> <table class="layout layout--article layout--1-column" border="0" width="100%" cellspacing="0" cellpadding="0"> <tbody> <tr> <td class="column column--1 scale stack" align="center" valign="top"> <table class="text text--article text--padding-vertical" border="0" width="100%" cellspacing="0" cellpadding="0"> <tbody> <tr> <td class="text_content-cell content-padding-horizontal" align="left" valign="top"> <p><strong>Dear Reader,</strong></p> <p>On behalf of our <strong>BUPE2024-Buprenorphine in Medicine</strong> conference co-chairs, Dr. Mellar Davis and Dr. Mary Lynn McPherson, we are reaching out to recruit additional presentations for the following specific topics to round out our BUPE2024 educational site. If you have expertise in these areas, we would appreciate an abstract for a 30-60 minute recorded or live presentation. We also have a section for video posters for late-breaking research on all buprenorphine topics.</p> <p align="center"><strong>BUPE2024 Questions</strong></p> <p>Main Questions:</p> <ul> <li>Why is buprenorphine not covered by health insurance? Why is it difficult to get insurance coverage?</li> <li>Why is buprenorphine excluded from health insurance formularies of prescription drugs for pain management?</li> <li>What is the DEA’s perspective on buprenorphine being excluded from formularies?</li> <li>What is the addiction medicine community’s perspective on prescribing buprenorphine for addiction treatment?</li> <li>What challenges do pharmacists face filling buprenorphine prescriptions?</li> <li>What are the implications of converting patients from buprenorphine treatment to other opioids?</li> <li>What is the safest way to wean patients off buprenorphine treatment?</li> <li>Should there be a front-line drug for pain management instead of initially prescribing potentially addictive meds like oxycodone? Buprenorphine?!</li> <li>How does buprenorphine compare to other opioids for pain management and addiction treatment?</li> <li>How does buprenorphine compare to other opioids regarding tolerance to achieve the same analgesic effect?</li> <li>What are the clinical usages/aspects of buprenorphine? Clinical pain management vs. addiction.</li> <li>Are there advantages or disadvantages of combining buprenorphine with other opioids?</li> <li>What is the best way to convert to buprenorphine? 1-Transition to TD buprenorphine, 2- Microdose?</li> <li>Myths regarding buprenorphine.</li> <li>Why is buprenorphine used on the street?</li> <li>Rotations from buprenorphine to other opioids.</li> <li>Buprenorphine versus naloxone in reversing opioid-induced respiratory depression, is it time for consideration?</li> <li>Utilization of buprenorphine in hospice and palliative medicine.</li> <li>The use of AI for decision support when prescribing buprenorphine and other opioids.</li> </ul> <p> </p> <p>Other ideas/topics:</p> <ul> <li>Issues on the fringe</li> <li>Practical aspects</li> <li>Conversion ratios</li> <li>Educating other physicians, families/patients</li> <li>Buprenorphine vs. another opioid</li> <li>Infographics</li> <li>Myths of buprenorphine</li> <li>A session of submitted questions that get asked on a regular basis.</li> </ul> <p> </p> <p>Presentation subjects we’d like to pursue:</p> <ul> <li>Health insurance</li> <li>Clinical</li> <li>Pharmacist</li> <li>Basic pharmacology</li> <li>Psychiatry</li> <li>DEA</li> <li>Basic science</li> <li>Opioid ethics</li> <li>Sons of buprenorphine</li> </ul> <p> </p> <p> </p> <p> </p> <p><strong>Please submit your presentation abstract by Monday, July 31, 2024, to help expand knowledge on buprenorphine's diverse role in pain management and addiction treatment. Thank You!</strong></p> <p align="center"> </p> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> <table class="layout layout--1-column" border="0" width="100%" cellspacing="0" cellpadding="0"> <tbody> <tr> <td class="column column--1 scale stack" align="center" valign="top"> <table class="text text--padding-vertical" border="0" width="100%" cellspacing="0" cellpadding="0"> <tbody> <tr> <td class="text_content-cell content-padding-horizontal" align="left" valign="top"> <p align="center"><strong>Submission Instructions</strong></p> <p align="center">1. <a href="https://wmpllc.org/ojs/index.php/jom/libraryFiles/downloadPublic/10" target="_blank" rel="noopener noreferrer">Download and complete the BUPE2024 Abstract Form</a></p> <p align="center">2. <a href="https://wmpllc.org/ojs/index.php/jom/libraryFiles/downloadPublic/9" target="_blank" rel="noopener noreferrer">Download and complete the disclosure form</a> (for each individual on abstract form)</p> <p align="center">3. <a href="https://wmpllc.org/ojs/index.php/jom/libraryFiles/downloadPublic/22" target="_blank" rel="noopener noreferrer">Download and complete the general release form</a> (for each presenter)</p> <p align="center">4. Email all completed forms together to <a href="mailto:jom@pnpco.com" target="_blank" rel="noopener noreferrer">jom@pnpco.com</a></p> <p align="center">For help, call 781-899 2702 ext. 108 from 9:00 AM - 5:00 PM ET.</p> <p align="center">of email us at<a href="mailto:jom@pnpco.com" target="_blank" rel="noopener noreferrer"> jom@pnpco.com</a></p> <p align="center">Deadline to Submit Forms: July 31, 2024</p> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table>

2024-07-17T13:30:06-04:00